259a_13_CT
Discover more at abcam.com/SimpleStep
Mix Wash Read. It’s that easy.
Discover our new single wash sandwich ELISA
assay offering improved performance.
SimpleStepTM ELISA
kits – make your
life easier
Advanced Sample & Assay Technologies
Better results — on any sequencing platform
Get the most from your NGS
NGS1113S1W
W_DPS
Discover new and innovative solutions,
dedicated for use with any NGS workflow
Streamline your next-generation sequencing (NGS) workflow and achieve
high-quality results you can rely on.
■ Highly specific and selective nucleic acid purification and target enrichment
■ Unbiased whole genome amplification from a single cell
■ High DNA library yields using optimized workflows that allow ~50% time-savings
■ Outstanding results on any sequencing platform
■ Intuitive, knowledge-based data interpretation for deeper insight into NGS results
Visit www.qiagen.com/goto/NGS to learn more!
Sample & Assay Technologies
Advertisement
Advertisement
Make ends meet.
Gibson Assembly® Cloning KitNew England Biolabs has revolutionized your laboratory’s
standard cloning methodology. The Gibson Assembly
Cloning Kit combines the power of the Gibson Assembly
Master Mix with NEB 5-alpha Competent E. coli, enabling
fragment assembly and transformation in just under two hours.
Save time, without sacrificing efficiency.
Making ends meet is now quicker and easier than ever before,
with the Gibson Assembly Cloning Kit from NEB.
IN-FUSION® is a registered trademark of Clontech Laboratories, Inc.
GENEART® is a registered trademark of Life Technologies, Inc.
GIBSON ASSEMBLY® is a registered trademark of Synthetic Genomics, Inc.
Visit NEBGibson.com to view the latest
tutorials and to try our primer design tool.
Some components of this product are manufactured
by New England Biolabs, Inc. under license from
Synthetic Genomics, Inc.
0
10
20
500
1000
1500
2000
2500
3000
In-Fusion®Gibson Assembly
GeneArt®
1 kb 3kb 5 kb
Numberofrecombinantcolonies
(x103)
Fragment size
Assembly reactions containing 25 ng of linear pUC19 vector and 0.04 pmolof each fragment were performed following individual suppliers’ recommendedprotocols and using the competent cells provided with the kit. The total numberof recombinant colonies was calculated per 25 ng of linear pUC19 vector addedto the assembly reaction.
Gibson Assembly Cloning Kit provides robust
transformation efficiencies
Join Keystone Symposia for Two Unique Events
HIV/AIDS:Strategies for an EndgameDecember 13, 2013 | 1:00–2:30 PMESTOur frst FREE, LIVEwebcast.
This 90-minute eventwill aim to determine the optimal strategy to endthe AIDS epidemic, with a particular focus on discussing themerits ofpre-exposure prophylaxis versus vaccines.
Moderator: BruceWalker
Panelists: Myron (Mike) Cohen, Betsy Herold, Julie McElrath and Gary Nabel
Visitwww.keystonesymposia.org/KSHIV to register and to submit
a question/topic that you would like addressed during the discussion.
Big Data in BiologyMarch 23–25, 2014 | San Francisco, California, USAOur frst SHORT, TWO-DAY symposium.
This conferencewill address the challenges of sharing, archiving, integratingand analyzing the vast amounts of biological data nowbeing generated.The eventwill bring together various research specialties that rarely interact,including plant scientists,medical geneticists, genomicists,microscopists andneurobiologists, aswell as computer scientists, computational biologists,mathematicians and technologists. Event sessions start at 8 AMonMarch 24.
Scientifc Organizers: Lincoln D. Stein,DoreenWare andMichael Schatz
Session Topics:
• Databases and Clouds
• Panel on Big Data Challenges and Solutions:Control Access to Individual Genomes• Personal Genomes• Imaging/Pharmacogenomics
Discounted Abstract Deadline:November 19, 2013Student/Postdoc Scholarship ApplicationDeadline:November 19, 2013Abstract Deadline:December 18, 2013Discounted RegistrationDeadline: January 21, 2014
For more information and to view the full program,
visitwww.keystonesymposia.org/14F2
CONFIRMED SPEAKERS(as of November 4, 2013):
Laura Clarke, EuropeanBioinformatics InstituteMarkGerstein, Yale UniversityDavid Haussler*, UC Santa CruzJill P. Mesirov, Broad InstituteJohnOverington, EuropeanMolecular Biology LaboratoryAjay Royyuru, IBMT.J.WatsonResearch CenterMichael Schatz, Cold SpringHarbor LaboratoryDan Stanzione, Universityof Texas at AustinLincoln D. Stein, OntarioInstitute for Cancer ResearchSusan Sunkin, Allen Institutefor Brain ScienceJason Swedlow, Universityof DundeeMattWood, AmazonWebServices, Inc.
*Keynote Speaker
www.keystonesymposia.org | 970.262.1230 | 800.253.0685
PNASwww.pnas.org
Call for 2013
Cozzarelli Prize
Nominations
The PNAS Editorial Board is nowaccepting nominations throughJanuary 10, 2014 for the 2013 CozzarelliPrize. This award recognizes scientificexcellence and will be given to six paperspublished in PNAS during 2013.
Nominations should be sent [email protected] and should include acitation and brief explanation of themerits of the work. The award recipientswill be recognized during the PNASEditorial Board Meeting and the NASAnnual Meeting Awards Ceremony onApril 27, 2014 in Washington, DC.
For more information and a list of previous winnersvisit www.pnas.org/cozzarelliprize.
ImagecourtesyofUniversity
ofCalifornia,B
erkeley.
Nicholas R. Cozzarelli, former PNAS Editor-in-Chief
Eppendorf®, the Eppendorf logo, Eppendorf PhysioCare Concept® and Eppendorf Reference® are registered Trademarks of Eppendorf AG, Germany.
All right reserved, including graphics and images. Copyright © 2013 by Eppendorf AG.
Eppendorf Reference® 2
»Reference« stands for extraordinary
precision and accuracy, a long service
life, and an ergonomic design. The new
Reference 2 boasts these proven Premium
characteristics and this operating philo-
sophy with its innovative state-of-the-art
technology; making it a reliable partner
for you and your demanding work.
> Single-button operation enables
ergonomic handling with reduced
operating efort
> High precision and accuracy providing
reliable pipetting results
> Quick and secure volume setting,
incl. volume lock
> RFID chip contains all relevant data
regarding the pipette
www.eppendorf.com/reference
The New Legend
Electronically submit your new product description or product literature information! Go to www.sciencemag.org/products/newproducts.dtl for more information.
Newly offered instrumentation, apparatus, and laboratory materials of interest to researchers in all disciplines in academic, industrial, and governmental organizations are
featured in this space. Emphasis is given to purpose, chief characteristics, and availability of products and materials. Endorsement by Science or AAAS of any products or
materials mentioned is not implied. Additional information may be obtained from the manufacturer or supplier.
����������������������������� ����������������� ����������
���������������� � ����
875www.sciencemag.org/products SCIENCE VOL 342 15 NOVEMBER 2013
�������������������� ���
���&�������&��&�����&����(��&�'(�����(&��'����&��&�&�(�� ��� �&����
�(�����&��'����&�('&���&�&���'(&���'���(&(�&�������'�('����&�((� (� &
'��(�����&����(����&��&���&�'�������&�������&��&�����&�'�����&
�&���� ��&�(�����(&�('&����'�('&���&�������&����&����(����&�'(�����&
�(&���&��'������&���'���(� & �� ���&�����'��!&���&��&��'����&� ����&���&
��������'�'�&����&�&�(���������&��������!&�� ���&�(&��'����&�� ��&'���
���&����(��&���&���&�(&�����&�&�(�� �&�'(�����(&���� �����&��&����'�����&
���&�������&�'(�����(&����( (��&(�&���&�������&��&�����&��'����&
� (��&�('&���&��'�����&(�&�&�'(���'&'���&(�&������&���&�(���� �&�&���(!&
�� ����&�((' �&����('�������&��&�(���&�(��(���!&��&'��(�����&
��&�'(�����(&��&�(���� �&(&�&'���&(�&��� ��&"��&�(&#�$�&�&�&� ��'��
����&�(&�'(�����&�� & ����&���!&���&�'������&��&������&��&���'����&
�&%���&��'��&�(���!&�(&�'��� �&�����&�����������&��&����������&(�&�&���&
�����&�&�( ��������&��� �����(��&
��������������
������������������� ����333���������6��������6�
������������������
�3��35���36�3 �6�����3�� 3�5� �5�3 5����65 3����3���3�� ���3 �63��3
������3��3 �55��3� �3 ����5�3�6������3 �55�5 3���3���3����3�5���3
������53����3� �5� 3��������3����3�5� ��5�3���3�� �3�� �� 3�5�3��������3
�56�3'-3��3�63'--3��3��3�5�35����3��3�63.--3��53��3.--/�3�����3
5����6 3�����3���56����6 3��5�6����6 3��3��5�6�����63��3���
������3 �����5���5� 3 ��3 �5� �5� 3 �63 ��3 56�����3 ��5�65����3���3 ���3
�����3��������36�3 ����5�3��3�� �6�3�5���3 �5� 3� ��3�� 3�5� �5�3
5����65 3�56���3���� � 3���3�3�����65�3�63���5��"�3�3 ���35����63
�56�30--1 36�3��56���5 3��3� ���36533��5����� 3��3�63�3 ���35����63�63
���3�6����36�3���3�� ���3���3�� �� 3��3��3�56����3���3�3��5 ��3� � 3
�5� �5�3����� 3�5� �5�35����3����� 34�0--3�����5���5�3�56�� 3���5�6��
���3�6534�0-- 3�66��3�6� 3������36��5����3 �55�53���3 ����5�3�����
��53!&0,3 ���� 3 ����# 3�����5� �5�3��5����3� ����� 3��3�35���36�3��� 3
6534���3 �5� 3��3��5 3� 3����3� 34��23��5�� 3�3��� �5��3
������
�653�6$3%**�!-#�0,&(�+(0+-)3 ����� ����8�5
�����������������
�����5�875� �5��57� ��7���7 5��58���7 5��7�87��5�����8��5 ���� !5�8�
���7����85 � � ��� !5 �87� �5 �������8 !5 �8��8 �5 7� ��7��!5 �8���
��5 �7���5 ���� !5��58���75���78��5875��78��57� ��7��!5���5�8���5
/1-52�����5�7�����875 ��5�8���5 '/-,�5���7������5 �����75 �78���5
�����7���7�5 �8�78�58��75 �5 7���5 � 5�78��5 � 5 �1-0�5 �85%+-0�5 "1*0�5 �85
1'(0�#�5�� ���5 �875 � �5���5 ���78��5 7� �78����7 !5 ���5�8���5 /1-5
2�����5�7�����875�8�78� 5�����7���7�5�78�5�����5�85%+-0�5"1'(0�#5
���53-�/0�5"3-�*0�#5 �������5��5�� 5�5+'-5 5�����75��5�5 ���5 ����5
���7�����5����5����5�����7 5��5�8511�*5������5"&�-5����8 �����#5
��5-�1&5��75"/�-56��#�5���5�8���5'/-,�5�����75 57��8������5�875� �5
���5��78��57� �78����7 �5�� 545265�����75�8�78� 5�����7���7� 5�78�5
�1-0�5�85+-0�5"1*0�5�851'(0�#5���53-�10�5"3-�/0�#5 ������5��5�5����
���5�7��5���7�����5����5����5�����7 5��5�851'�'5�6�5"*�15.6�#5��5
-�,)5��75"1-56��#�5
�����������
�875�8$5(--�//)�+',)555999���"�<�� ����"�<�9
������������� �� ���
���9 ���9 ������<9 �<<�9 <�9 ����1���9 ��; <9 2"*"-9 �<;��;�9 ����� 9
�9 <�� ������9 ��9 �<��;������ ��9 ���<;���9 �����<���9 �<;9 ���9 ���
�;��<9 �$����9 &�1�(9 �$����9 ����9 �;<�9 �;���� 9 ���9 � 9 ���
����%9 �<���%9 ��9 �<9�<;;��9 �$����9 �����<;� "9�������< 9 �
�����9 �<��9��<��9 ��<��9 � 9����9 ��;�����9 �$����9���� 9 ���9 � 9 �<9
�<;;��9 ������$9 ���� 9 <;9 ���9 6��<:���9 ��;���9 �;�����9 �� ���9
�;<�9�����9����<�<�� "9�<��9����;9��;��< 9��9<�9��9��������9
9�1�9����9� �9� ��; <9��� �;���� 9��9�9<���96���9��;'<�9
�<���9&6��(9<�9�<��99<���;9�1�9���� 9�;<�;�� "9#��9���9��9
����<�<��9 ������9;��< 9<�9�97 �����89��9�97�<�;<�89�;�9� ��9�<9���
��;��9�9�<��;���9;��<9��� �;��99�:5�9�<;9���;�9;��<9& �����9��
����9��9 �����9��� 9�<�;<�("9���9���� 9�;�9����9<9���9�� 9<�9����� 9
9�<��;���%9��� �9���<����9��� �;����9<�9< �9 &� ��; <(9��9�9
<���96��"9
�����������
!<;9�<)9+++�.,3�32.09 ���" <������� "�<�
������ ������������
���9���< <;�9/9��9 9�� ���9�<9����9���9��� 9<�9���<;��<;� 9���9���9��������9��;<������9;�$�;�9
;���9��9����;���9 �;����9�;��9��9�<;�� �9����"9��9�;<��� 9���9��������9����9���<� 9��9�<9 �9 ����� 9�<9
;�9�<��;;����9��9�<��������9���������"9���9�������� 9�;<���9�;<������9����;9 ���� %9����9
�;��9�9����9��;�< �9�<;9�<��9�;<�����9���9<��;��<;9��9���9���� �;"9���;<���9������9� ���� 9����;��9 �<�9
���9 ���� 9<�9���9 �;����4 9<��;��<"9���9���< <;�9/9��9��#9 <����;�9�� 9���9�������9�<9�;<���9
�����;� 9�<9��������9�!�9239:�;�9339�<������"9�� 9���<� 9���;���������9���<;��<;� 9�<9����9!��9;����
���< 9�<;9�����;<�9;��<;�9'����9 � ��� 9�����9�����;� 9 ���9� 9�� �<;�9�<�;<����9���� %9����9�;��9
�������� %9��9������9;��<;��9�����;� "9�9����<%9���9��9 <����;�99�<��9�!�9��9<��!�9�<�� 9
�;<��� 9������9��<;�9��9���<;�9�������� %9�������9����9 �<;���%9��9����9/-���9�<��������9�<9���<�9
<��;��<9���9��;;��9#�<� 9<��;���9 � ��� "9
������ ��������������
!<;9�<)9+00�,+,�2-./999999���"$������;<��"�<�
Brought to you by the
Science/AAAS Custom
Publishing OfficeWebinar sponsored by
Exome Sequencing in Today’s Lab:Shifting the Paradigm in Translational and Clinical Research
REGISTER NOW!webinar.sciencemag.org
Next generation sequencing technologies have enabled a rapid expansion
toward the understanding of inherited disorders, cancer biology, drug devel-
opment, and treatment resistance. Exome sequencing has been increasingly
and successfully applied in the clinical research setting for identifying com-
mon single nucleotide variants, copy number variations, and small insertions
or deletions as well as rare de novo mutations that may explain Mendelian,
complex, and rare genetic disorders. Recent advancement in rapid and
low-cost exome sequencing make it an attractive alternative to traditional
targeted gene panel sequencing for clinical research, while maintaining the
possibility of discovering mutations in genes previously not associated with
a disorder. Furthermore, the exome encompasses approximately 1% of
the genome, yet contains approximately 85% of disease-causing muta-
tions, making exome sequencing easier and cheaper than whole genome
sequencing for identifying disease-causing variants in research.
Researchers are now applying proband-father-mother (trio) exome
sequencing to uncover variants that potentially either cause or modify the
condition under study. In this webinar, the audience will learn about the cur-
rent applications of exome sequencing in clinical research and its impact on
the future of health care.
During the webinar, the speakers will:
• Detail their clinical research exome workflow from DNA to data analysis
• Compare exome sequencing to other variant screening approaches
• Shed light on the current paradigm shift to exome sequencing for clinical
research
• Discuss how this shift may impact future clinical applications of exome
sequencing
• Answer your questions live on air!
Wednesday, December 4, 201312 noon Eastern, 9 a.m. Pacific, 5 p.m. UK, 6 p.m. Central Europe
Christian Marshall, Ph.D.
The Hospital for Sick Children
Toronto, Canada
Christian Gilissen, Ph.D.
Radboud University Medical Centre
Nijmegen, The Netherlands
Speakers
Key applications:
• Cancer Biology
• Stem Cell Research
• Developmental Biology
• Neurobiology
• Immunobiology
• Lentivirus Production
• CHO Cell Protein Production
Don’t let old toxic transfection technology
get in the way of your science.
FuGENE® HD provides the
power to transfect
virtually any cell type
while maintaining
biologically relevant
cell signaling responses.
To discover the power of FuGENE® HD for your biology, request a free sample at
www.promega.com/pathwaybiology
In this BaF3 cell model of NF-kB luciferase induction, only
FuGENEÆ HD and FuGENEÆ 6 are able to create a usable assay.
10
81
8M
A
80000
RLU
FHD
F6
LTX+
L2K
60000
40000
20000
0
0–6 – 4 –2 2 4
FuGENE®
HD
FuGENE® is a registered trademark of Fugent, LLC.
©2013 Promega Corporation. All rights reserverd. 4882